AXIM Biotechnologies Applauds FDA’s Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

NEXT STORY
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
PREV STORY
First Stop Health Adds Virtual Primary Care as Whole-Person, Digital-First Service to Address Urgent, Preventive and Chronic Care Needs for Members
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL

HALIFAX, Nova Scotia, March 28, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

author_avatar
NASDAQ Market News

Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings

MADISON, Wis., May 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), ...

author_avatar
NASDAQ Market News

Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition

Exclusive worldwide license to lentiviral vector gene therapy constitutes the first transaction of Axovant’s ...

author_avatar
NASDAQ Market News